Michael Sperling - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Michael Sperling's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Michael Sperling
Verified
Late Researcher, TODAY
New York
Beats
State & Local GovernmentBusiness Transportation Urban Planning Mobility
Content
Seizure freedom and reducing the risk of sudden unexpected death in patients with focal epilepsy treated with cenobamate or other antiseizure medications
By Michael Sperling, William Rosenfeld, JOhn Watson, John Watson, Pavel Klein| Wiley Online Library Verified Seizure freedom has been a goal of epilepsy treatment for >25 years, but rates of seizure freedom have changed little during this time. Uncontrolled FBTCS are the greatest risk factor for SUDEP. Adjunctive cenobamate treatment is associated with rapid and sustained rates of freedom from FBTCS in drug-resistant focal epilepsy patients. Effective prescribing practices and clear communication can help patients attain seizure freedom and significantly reduce their risk of SUDEP.
By David Halpern, Bradley Lega, Chengyuan Wu, Michael Sperling| Nature Verified AbstractCan the brain improve the retrievability of an experience after it has occurred? Systems consolidation theory proposes that item-specific cortical reactivation during post-encoding rest periods facilitates the formation of stable memory representations, a prediction supported by neural evidence in humans and animals. Such reactivation may also occur on shorter timescales, offering a potential account of classic list memory phenomena but lacking in support from neural data.
Seizure freedom and reducing the risk of sudden unexpected death in patients with focal epilepsy treated with cenobamate or other antiseizure medications
By Michael Sperling, William Rosenfeld, JOhn Watson, John Watson, Pavel Klein| Wiley Online Library Verified Seizure freedom has been a goal of epilepsy treatment for >25 years, but rates of seizure freedom have changed little during this time. Uncontrolled FBTCS are the greatest risk factor for SUDEP. Adjunctive cenobamate treatment is associated with rapid and sustained rates of freedom from FBTCS in drug-resistant focal epilepsy patients. Effective prescribing practices and clear communication can help patients attain seizure freedom and significantly reduce their risk of SUDEP.
Company Info
TODAY
We are a student driven media agency! We help independent businesses become bolder, more creative and bigger.
New York, United States
+1 617-737-6157
Founded: 2017